The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension

Chest

Volumn 141, Issue 1, 2012, Pages 36-42

  Rich, Jonathan D ^a   Glassner, Cherylanne ^a   Wade, Michael ^b   Coslet, Sandra ^a   Arneson, Carl ^b   Doran, Aimee ^b   Gomberg Maitland, Mardi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNITED THERAPEUTICS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DILUENT; PROSTACYCLIN; UNIPROST;

ADULT; ARTICLE; BLOOD CULTURE; CATHETER INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORYNEBACTERIUM; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; PH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEUS MIRABILIS; PSEUDOMONAS; PULMONARY HYPERTENSION; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS;

EID: 84855468771     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0245     Document Type: Article

References (24)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-223. (Pubitemid 17137857)
2. Barst RJ, Rubin LJ, Long WA, et alThe Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-302.
3. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension:the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.
4. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension:prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-788. (Pubitemid 34925627)
5. Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep. 2007;56(8):170-172.
6. Kallen AJ, Lederman E, Balaji A, et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol. 2008;29(4):342-349. (Pubitemid 351416985)
7. Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcusassociated central venous catheter infection in patients with pulmonary arterial hypertension. Chest. 2004;126(1):90-94. (Pubitemid 38943122)
8. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271(20):1598-1601.
9. Smith RL, Meixler SM, Simberkoff MS. Excess mortality in critically ill patients with nosocomial bloodstream infections. Chest. 1991;100(1):164-167.
10. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005;172(12):1586-1589. (Pubitemid 43076550)
11. McLaughlin VV, Gaine SP, Barst RJ, et alTreprostinil Study Group. Effi cacy and safety of treprostinil:an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41(2):293-299. (Pubitemid 36135255)
12. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31(4):891-901.
13. Zaccardelli D, Phares K, Jeffs R, Doran A, Wade M. Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan. Int J Clin Pract. 2010;64(7):885-891.
14. Remodulin [package insert]. Research Triangle Park, NC :United Therapeutics Corporation;2008.
15. Flolan [package insert]. Research Triangle Park, NC:GlaxoSmithKline; 2008.
16. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension:1982-2006. Eur Respir J. 2007;30(6):1103-1110. (Pubitemid 351194756)
17. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL;Scientifi c Leadership Council of the Pulmonary Hypertension Association. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl. 2008;(160):5-9. (Pubitemid 352000590)
18. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths:fi nal data for 2006. Natl Vital Stat Rep. 2009;57(14):1-134.
19. Akagi S, Matsubara H, Ogawa A, et al. Prevention of catheterrelated infections using a closed hub system in patients with pulmonary arterial hypertension. Circ J. 2007;71(4):559-564. (Pubitemid 46513466)
20. Yap RL, Mermel LA. Micrococcus infection in patients receiving epoprostenol by continuous infusion. Eur J Clin Microbiol Infect Dis. 2003;22(11):704-705. (Pubitemid 37491628)
21. Edwards JR, Peterson KD, Andrus ML, Dudeck MA, Pollock DA, Horan TC;National Healthcare Safety Network Facilities. National Healthcare Safety Network (NHSN) report, data summary for 2006 through 2007, issued November 2008. Am J Infect Control. 2008;36(9):609-626.
22. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices:a systematic review of 200 published prospective studies. Mayo Clin Proc. 2006;81(9):1159-1171. (Pubitemid 44316281)
23. Phares KR, Weiser WE, Miller SP, Myers MA, Wade M. Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents. Am J Health Syst Pharm. 2003;60(9):916-922. (Pubitemid 36749017)
24. Ivy DD, Calderbank M, Wagner BD, et al. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. Infect Control Hosp Epidemiol. 2009;30(9) :823-829.